Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.

Data

Health Data

Aitia

Colin Hill

shahid yatoo

Zena Sfeir Gehchan (She/Her)

So-Youn Shin

Mitchell Rosen

McLaren Gould

Ken Levine

Joe Donahue

Jeanne Latourelle

Jan Berger

QIAN DU

Charles Homan

Bruce Church

The Business Development team at Aitia is responsible for identifying and securing strategic partnerships, fostering collaborations with top pharmaceutical companies, academic research centers, and other key stakeholders. They work to expand Aitia's reach in applying Causal AI and Digital Twins in drug discovery and development. This team is instrumental in driving growth opportunities, negotiating deals, and aligning business strategies to advance the company's mission of revolutionizing treatments for complex diseases.

Business Development

Engineering Team

Leadership Team

Business Development

About

Team members

Other teams at Aitia

Engineering Team

Leadership Team